Jonathan A. Fletcher
Impact in
- Gastroenterology top 0.01%
- Gastrointestinal Tumor Research and Treatment
- Pulmonary and Respiratory Medicine top 0.05%
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
Papers in
-
- Sarcoma Diagnosis and Treatment 69
- Gastric Cancer Management and Outcomes 25
-
- Gastrointestinal Tumor Research and Treatment 79
- Co-authors
- Michael C. Heinrich (48 shared papers)Christopher L. Corless (29 shared papers)Jeffrey S. Ross (10 shared papers)George D. Demetri (35 shared papers)Christopher D.�M. Fletcher (21 shared papers)Samuel Singer (6 shared papers)Anette Duensing (8 shared papers)Laura McGreevey (4 shared papers)
- Journals
- Journal of Clinical Oncology (28 papers)Cancer Research (15 papers)Oncogene (10 papers)Genes Chromosomes and Cancer (9 papers)Clinical Cancer Research (7 papers)
- Partner nations
- United StatesGermanyChina
In The Last Decade
Jonathan A. Fletcher
202 papers receiving 22.8k citations
Jonathan A. Fletcher's Hit Papers
Peers
Comparison fields: 5 of 142
- Gastroenterology 8.5k
- Pulmonary and Respiratory Medicine 11.0k
- Neurology 3.2k
- Oncology 5.5k
- Hematology 2.0k
Countries citing papers authored by Jonathan A. Fletcher
This map shows the geographic impact of Jonathan A. Fletcher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan A. Fletcher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan A. Fletcher more than expected).
Fields of papers citing papers by Jonathan A. Fletcher
This network shows the impact of papers produced by Jonathan A. Fletcher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan A. Fletcher. The network helps show where Jonathan A. Fletcher may publish in the future.
Co-authors
The 25 scholars most cited alongside Jonathan A. Fletcher, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 203 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors Hit paper breakdown → | 2003 | 1767 |
| 2 | Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor Hit paper breakdown → | 2003 | 1719 |
| 3 | Biology of Gastrointestinal Stromal Tumors Hit paper breakdown → | 2004 | 906 |
| 4 | The HER‐2/ neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy Hit paper breakdown → | 1998 | 799 |
| 5 | Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT Hit paper breakdown → | 2008 | 750 |
| 6 | Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors Hit paper breakdown → | 2006 | 609 |
| 7 | PAX8-PPAR γ 1 Fusion in Oncogene Human Thyroid Carcinoma Hit paper breakdown → | 2000 | 600 |
| 8 | Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor Hit paper breakdown → | 2008 | 564 |
| 9 | Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients Hit paper breakdown → | 1992 | 544 |
| 10 | 2003 | 445 | |
| 11 | Correlation of Kinase Genotype and Clinical Outcome in the North American Intergroup Phase III Trial of Imatinib Mesylate for Treatment of Advanced Gastrointestinal Stromal Tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group Hit paper breakdown → | 2008 | 436 |
| 12 | BRD4-NUT fusion oncogene: a novel mechanism in aggressive carcinoma. | 2003 | 380 |
| 13 | 2004 | 374 | |
| 14 | 2002 | 363 | |
| 15 | 1995 | 363 | |
| 16 | 2007 | 342 | |
| 17 | 2007 | 323 | |
| 18 | 2005 | 323 | |
| 19 | 2002 | 308 | |
| 20 | 1998 | 301 |
About Jonathan A. Fletcher
Jonathan A. Fletcher is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology, Molecular Biology, Hematology and Oncology, having authored 203 papers that have together received 23.4k indexed citations. Recurring topics across this work include Gastrointestinal Tumor Research and Treatment (79 papers), Sarcoma Diagnosis and Treatment (69 papers), Gastric Cancer Management and Outcomes (25 papers), Neurofibromatosis and Schwannoma Cases (23 papers), Platelet Disorders and Treatments (17 papers), Chronic Myeloid Leukemia Treatments (16 papers), Gastrointestinal disorders and treatments (15 papers) and Renal and related cancers (12 papers). The work is most often cited by research in Gastroenterology (8.5k citations), Pulmonary and Respiratory Medicine (11.0k citations), Neurology (3.2k citations), Oncology (5.5k citations) and Hematology (2.0k citations). Jonathan A. Fletcher has collaborated with scholars based in United States, Germany and China. Frequent co-authors include Michael C. Heinrich, Christopher L. Corless, Jeffrey S. Ross, George D. Demetri, Christopher D.�M. Fletcher, Samuel Singer, Anette Duensing, Laura McGreevey, Margaret von Mehren and Antonio R. Pérez‐Atayde. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Oncogene, Genes Chromosomes and Cancer and Clinical Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.